News & Events
NEW YORK (GenomeWeb News) – Molecular diagnostics company Insight Genetics said on Monday it has been awarded two SBIR contracts from the National Cancer Institute to develop companion diagnostic tests aimed at lung cancer. The contracts, which total about $1.7 million, will go toward developing tests to identify and characterize specific genetic mutations in lung cancer patients. The tests would help physicians decide which therapies are best suited for individual patients.
Insight Genetics Awarded Two National Cancer Institute Contracts to Enhance Precision in Cancer Care
Insight Genetics, Inc. today announced it has received two Small Business Innovation Research (SBIR) contracts from the National Cancer Institute (NCI) to continue its work developing diagnostic tests that identify and characterize specific genetic mutations in lung cancer patients. These companion diagnostic tests will be vital tools in enhancing the accuracy of cancer diagnosis and treatment, assisting physicians in determining which targeted cancer therapies are appropriate for specific patients.
GENOMEWEB - Insight Genetics Wins $1.5M Grant to Begin Clinical Testing for ALK Mutation CDx on Qiagen Platform
Insight Genetics has been awarded a contract from the National Cancer Institute worth nearly $1.5 million to begin clinical testing of its qPCR-based assay for ALK mutations in lung cancer. The test, which is based on intellectual property licensed from St. Jude Children's Research Hospital and being developed on a Qiagen real-time PCR system, is on track to soon be offered as a research-use-only assay, and as a CE-marked kit in the second quarter of next year, the company said this week.
Insight Genetics has partnered with Kindstar Globalgene (Beijing) Technology, Inc., to improve cancer diagnosis and care throughout China, Hong Kong and Macau. In July 2012, Kindstar will begin offering Insight Genetics’ Insight ALK Screen™ lung cancer test to help clinicians better identify patients with ALK-positive tumors. The companies plan to collaborate on the creation of future tests to broaden the reach of personalized cancer care in China and surrounding regions.
Insight Genetics announced a worldwide licensing agreement with Clarient Diagnostic Services, Inc., a GE Healthcare company, for the anaplastic lymphoma kinase (ALK) biomarker. Clarient intends to develop a new test to detect increased transcription of the ALK gene, results from which are helpful to clinicians in determining when to prescribe ALK-inhibitor cancer treatments.